Leptin (LEP)
Overview
Leptin is a 16 kDa adipokine encoded by the LEP gene and secreted mainly by white adipose tissue in proportion to fat mass, making it the body's signal of stored energy. It acts through the leptin receptor (LEP-R) in the hypothalamic arcuate nucleus, stimulating anorexigenic POMC neurons and inhibiting orexigenic AgRP/NPY neurons to suppress food intake and permit energy expenditure. The receptor is a class I cytokine receptor with no intrinsic catalytic activity: ligand binding brings together receptor chains whose associated JAK2 molecules trans-phosphorylate each other and then the receptor tail, recruiting and activating signal transducer and activator of transcription 3 (STAT3), with PI3K/AKT and AMPK cascades alongside. Its own feedback inhibitors, SOCS3 and the phosphatase PTP1B, terminate the signal — and are also implicated in blunting it chronically. That is the paradox of the hormone: people with obesity have high circulating leptin yet behave as though they have none, a resistance attributed to saturable transport across the blood–brain barrier and to attenuated receptor signaling centrally, and one that intersects with insulin, glucagon-like peptide-1 (GLP-1) (GLP-1) and AMPK pathways.
Leptin's discovery raised the expectation that giving it would treat obesity, and the outcome defines the field: recombinant leptin corrects the severe hyperphagia and obesity of congenital leptin deficiency almost completely, and is approved for generalized lipodystrophy, where fat tissue and therefore leptin are absent — but it does little in common obesity, where the hormone is already abundant. Leptin is better understood as a starvation signal than a satiety one, since falling levels defend body weight far more forcefully than rising levels restrain it, which is also why the fall in leptin after weight loss drives the compensatory hunger that follows.
Beyond metabolism, leptin has pleiotropic effects in reproduction — where it permits puberty and fertility only when energy stores suffice — and in immune modulation, bone metabolism, cardiovascular regulation and oncology. It shapes inflammatory cytokine networks, interacting with interleukin-6 and C-reactive protein (CRP), and modulates coagulation. In placental biology, LEP expression serves as a marker of trophoblast function and metabolic adaptation in pregnancy. Leptin resistance, frequently co-occurring with insulin resistance and type 2 diabetes, is a central feature of obesity-related metabolic dysfunction.
Recent Publications Summary
Recent studies have established leptin's multifaceted role in metabolic homeostasis and its responsiveness to therapeutic interventions. In adults with hypertension and obesity, a 16-week combined aerobic exercise and hypocaloric diet intervention reduced serum leptin concentrations by 36% in the exercise group and 23% in controls, with body mass index emerging as an independent predictive factor 42082343May. Leptin levels also show sensitivity to bariatric surgery, where metabolic improvements following weight-reduction procedures correlate with altered adipokine levels, including leptin, that may mediate improved maternal cardiovascular function in pregnancies following these interventions 42240794Jun. In diabetic models, recombinant leptin treatment improved glucose homeostasis and reduced food intake in type 2 diabetic rats, demonstrating its direct metabolic effects, while computational modeling of semaglutide-responsive mechanisms highlighted leptin and leptin sensitivity as key nodes modulating weight and metabolic regulation alongside GLP-1 and glucose homeostasis 41875058Mar41969210Apr.
Placental leptin dynamics appear critical to pregnancy complications, particularly gestational diabetes mellitus, where transcriptomic analyses revealed LEP as significantly downregulated in gestational diabetic placentas compared to controls, alongside altered pathways governing glucose transport and amino acid metabolism 42175401May. In metabolically stressed states, such as peripartal hyperketonemia in cattle, leptin expression increased substantially in placental tissues and showed positive correlations with β-hydroxybutyrate and its receptor ObRb, suggesting leptin's role as a metabolic stress sensor linking adipocytokine signaling to systemic metabolic imbalance 42573864Aug.
Leptin's involvement extends to immune and inflammatory signaling, particularly in severe conditions. In critically ill COVID-19 patients, elevated leptin levels showed statistically significant associations with coagulation disorders and inflammatory markers including IL-6, ferritin, and C-reactive protein, implicating leptin in the cross-talk between inflammation and thrombosis 42065184May. In fibromyalgia pathophysiology, leptin exerts pro-nociceptive effects through its ObRb receptor, engaging JAK2/STAT3 signaling to amplify macrophage-driven neuroinflammation within sensory ganglia and sustain peripheral sensitization 41942028Apr. Molecular studies indicate that PTP1B negatively regulates leptin receptor tyrosine kinase signaling, and natural compounds capable of inhibiting PTP1B while stimulating AMPK may restore leptin and insulin pathway engagement in metabolic dysfunction 41831381Mar.
What Changes, What Holds
1. Recombinant leptin improves glucose homeostasis in type 2 diabetic rats
NEW DIRECTION Improved glucose control in type 2 diabetic rats 41875058Mar marks a new therapeutic direction: recombinant leptin shows efficacy beyond the congenital deficiency and lipodystrophy approved by the Overview, which emphasizes little effect in common obesity. Whether this translates to humans remains entirely unsettled—single animal studies cannot establish clinical benefit—but diabetic animals represent a distinct metabolic context warranting investigation as leptin remains unexplored therapeutically in type 2 diabetes despite documented interactions between leptin and insulin pathways.
2. Placental leptin is downregulated in gestational diabetes, reflecting altered metabolic adaptation
REINFORCES Downregulation of LEP in gestational diabetic placentas 42175401May reinforces the Overview's positioning of placental leptin as a metabolic marker, now showing specific dysregulation when placental metabolism is impaired by gestational diabetes. Leptin's role as a metabolic stress sensor emerges in hyperketonemic bovine models 42573864Aug, hinting at active regulation beyond marker status—but cattle studies cannot directly establish human placental mechanism. Combined, these findings sharpen understanding of LEP's adaptive role in pregnancy without contradicting the baseline.
3. Leptin exerts pro-nociceptive effects in fibromyalgia, extending its pleiotropic role to pain modulation
NEW DIRECTION Leptin's pro-nociceptive effects in fibromyalgia, delivered via JAK2/STAT3-driven macrophage-mediated neuroinflammation 41942028Apr, establish pain sensitization as a previously unreported pleiotropic role: the Overview catalogs immunity, bone, cardiovascular, reproduction, and oncology but not pain. Leptin antagonism thus emerges as a potential pain target, distinct from its energy and inflammatory roles. Association in a single condition cannot yet establish leptin as a general pain regulator, limiting the finding to fibromyalgia specifically.
Overview update candidates: Placental LEP dysregulation in gestational diabetes (entry 2) is established enough to augment the baseline; entries 1 and 3 remain preliminary.
leptin (lep)
Background Contexts
In the literature, the biological baseline, pathological conditions, or disease models commonly surrounding leptin (lep) are described as follows:
- obesity (Disease) — 3 papers: PMIDs 42442304, 42159845, 41969210
- inflammation (Biological Process) — 2 papers: PMIDs 42507057, 42031028
- type 2 diabetes (Disease) — 2 papers: PMIDs 41940860, 41875058
- acute inflammation (Biological Process) — 1 paper: PMIDs 42031028
- adipokine (Protein) — 1 paper: PMIDs 42240794
- airway remodelling (Biological Process) — 1 paper: PMIDs 42031028
- appetite regulation (Biological Process) — 1 paper: PMIDs 42533605
- asthma (Disease) — 1 paper: PMIDs 42031028
- atherosclerosis (Disease) — 1 paper: PMIDs 42507057
- Beta-2-microglobulin (Gene) — 1 paper: PMIDs 42191305
- breast cancer (Disease) — 1 paper: PMIDs 41995722
- cardiac remodelling (Other) — 1 paper: PMIDs 42031028
Methodologies & Technologies Used
Researchers utilize the following experimental methods, imaging platforms, computational models, or biological reagents to study leptin (lep):
- high-fat diet (Other) — 2 papers: PMIDs 42442304, 42159845
- Rat (Organism) — 2 papers: PMIDs 42533605, 42442304
- 1925 DEGs (Biological Process) — 1 paper: PMIDs 42175401
- adult male Wistar rats (Organism) — 1 paper: PMIDs 41942028
- Aerobic Exercise Training (Technology) — 1 paper: PMIDs 42082343
- Age (Other) — 1 paper: PMIDs 42507057
- Automated Edge-Detection Software (Technology) — 1 paper: PMIDs 42507057
- Beta-stiffness (Clinical Metric) — 1 paper: PMIDs 42507057
- Biochemical indicator (Clinical Metric) — 1 paper: PMIDs 42573864
- CAMP (Biological Process) — 1 paper: PMIDs 42152582
- cAMP-dependent protein kinase catalytic subunit (PKA-C) (Protein) — 1 paper: PMIDs 42152582
- Cannabisin A (Chemical) — 1 paper: PMIDs 41831381
Molecular Interventions & Targets
The primary molecular pathways, regulatory genes, enzymes, or therapeutic agents actively targeted and manipulated in relation to leptin (lep) include:
- Insulin Therapy (Therapy) — 2 papers: PMIDs 41969210, 41831381
- 18-β-glycyrrhetinic acid (Chemical) — 1 paper: PMIDs 42031028
- ACTC1 (Gene) — 1 paper: PMIDs 42175401
- Activated Partial Thromboplastin Time (Clinical Metric) — 1 paper: PMIDs 42065184
- adiponectin (Protein) — 1 paper: PMIDs 42573864
- Adiponectin (APN) (Protein) — 1 paper: PMIDs 42240794
- ADIPOR1 (Protein) — 1 paper: PMIDs 42573864
- agouti-related protein (Protein) — 1 paper: PMIDs 41969210
- AMP-activated protein kinase alpha 1 (AMPKα1) (Protein) — 1 paper: PMIDs 41831381
- bacterial lipopolysaccharide (Other) — 1 paper: PMIDs 42031028
- blood glucose (Clinical Metric) — 1 paper: PMIDs 41969210
- Bodyweight (Clinical Metric) — 1 paper: PMIDs 41969210
Observed Outcomes & Phenotypes
The phenotypic changes, physiological endpoints, or clinical metrics observed and measured in connection with leptin (lep) include:
- body weight (Clinical Metric) — 2 papers: PMIDs 42533605, 42159845
- Caspase-3 (CASP3) (Protein) — 2 papers: PMIDs 42442304, 42152582
- insulin (Protein) — 2 papers: PMIDs 42533605, 42159845
- Lactate dehydrogenase A (LDHA) (Protein) — 2 papers: PMIDs 42152582, 41875058
- LEPR (Protein) — 2 papers: PMIDs 42573864, 41995722
- malondialdehyde (Biological Process) — 2 papers: PMIDs 42442304, 42159845
- resistin (Protein) — 2 papers: PMIDs 42573864, 42152582
- Acyl-ghrelin (Protein) — 1 paper: PMIDs 42533605
- adiponectin (Protein) — 1 paper: PMIDs 42159845
- Adiponectin (APN) (Protein) — 1 paper: PMIDs 42152582
- ADIPOR1 (Protein) — 1 paper: PMIDs 42573864
- adipose tissue (Clinical Metric) — 1 paper: PMIDs 42159845
General Takeaways & Clinical Potentials
The high-level concepts, clinical translations, and overarching conclusions proposed in the research surrounding leptin (lep) are summarized below:
- Adipokine gene expression analysis (Biological Process) — 1 paper: PMIDs 42573864
- Anti-inflammatory (Therapy) — 1 paper: PMIDs 42031028
- anticancer activities (Other) — 1 paper: PMIDs 42152582
- antioxidant (Other) — 1 paper: PMIDs 42031028
- autophagy (Biological Process) — 1 paper: PMIDs 42159845
- chronic administration of recombinant leptin (Therapy) — 1 paper: PMIDs 41875058
- Chronic conditions (Disease) — 1 paper: PMIDs 42031028
- Dialysis Monitoring (Clinical Metric) — 1 paper: PMIDs 42191305
- Dialysis Performance (Clinical Metric) — 1 paper: PMIDs 42191305
- Energy Balance Regulation (Biological Process) — 1 paper: PMIDs 42533605
- Episodic Ghrelin-mediated Pathway (Pathway) — 1 paper: PMIDs 42533605
- exercise prescription (Other) — 1 paper: PMIDs 42533605